Figures
Abstract
Background
Previous studies have demonstrated gaps in achievement of low-density lipoprotein-cholesterol (LDL-C) goals among U.S. individuals at high cardiovascular disease risk; however, recent studies in selected populations indicate improvements.
Objective
We sought to define the longitudinal trends in achieving LDL-C goals among high-risk United States adults from 1999–2008.
Methods We analyzed five sequential population-based cross-sectional National Health and Nutrition Examination Surveys 1999–2008, which included 18,656 participants aged 20–79 years. We calculated rates of LDL-C goal achievement and treatment in the high-risk population.
Results
The prevalence of high-risk individuals increased from 13% to 15.5% (p = 0.046). Achievement of LDL-C <100 mg/dL increased from 24% to 50.4% (p<0.0001) in the high-risk population with similar findings in subgroups with (27% to 64.8% p<0.0001) and without (21.8% to 43.7%, p<0.0001) coronary heart disease (CHD). Achievement of LDL-C <70 mg/dL improved from 2.4% to 17% (p<0.0001) in high-risk individuals and subgroups with (3.4% to 21.4%, p<0.0001) and without (1.7% to 14.9%, p<0.0001) CHD. The proportion with LDL-C ≥130 mg/dL and not on lipid medications decreased from 29.4% to 18% (p = 0.0002), with similar findings among CHD (25% to 11.9% p = 0.0013) and non-CHD (35.8% to 20.8% p<0.0001) subgroups.
Conclusion
The proportions of the U.S. high-risk population achieving LDL-C <100 mg/dL and <70 mg/dL increased over the last decade. With 65% of the CHD subpopulation achieving an LDL-C <100 mg/dL in the most recent survey, U.S. LDL-C goal achievement exceeds previous reports and approximates rates achieved in highly selected patient cohorts.
Citation: Tattersall MC, Gangnon RE, Karmali KN, Cullen MW, Stein JH, Keevil JG (2013) Trends in Low-Density Lipoprotein Cholesterol Goal Achievement in High Risk United States Adults: Longitudinal Findings from the 1999–2008 National Health and Nutrition Examination Surveys. PLoS ONE 8(4): e59309. https://doi.org/10.1371/journal.pone.0059309
Editor: Rosa Maria Affonso Moysés, Universidade de São Paulo, Brazil
Received: August 3, 2012; Accepted: February 15, 2013; Published: April 2, 2013
Copyright: © 2013 Tattersall et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This investigation was supported by the National Institutes of Health, under Ruth L. Kirschstein National Research Service Award T32 HL 07936 from the National Heart Lung and Blood Institute to the University of Wisconsin-Madison Cardiovascular Research Center. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
LDL-C reduction is a central component of coronary heart disease (CHD) risk reduction [1]. Over the past two decades numerous clinical trials have demonstrated that lowering LDL-C reduces cardiovascular risk [2]–[11]. Individuals at highest risk of a cardiovascular event derive the greatest benefit from lowering of LDL-C and achievement of LDL-C goals [12]. In the United States, clinical guidelines have been modified to reflect the importance of LDL-C goal achievement in high-risk individuals. In 1993, the National Cholesterol Education Program’s Adult Treatment Panel (ATP) II [13] recommended an LDL-C goal of <100 mg/dL for patients with CHD. In 2001, the ATP III added CHD “equivalent” conditions to the population appropriate for an LDL-C of <100 mg/dL [1]. In 2004, an ATP III update presented an optional high-risk goal of an LDL-C <70 mg/dL [12]. Despite the importance of LDL-C reduction, an achievement gap in U.S. individuals at high cardiovascular risk has been described [14]–[15]. One year after the ATP III recommendations to treat those at high risk to an LDL-C <100 mg/dL, only 32% of the high-risk population in the U.S. met this goal [14]. Over the past decade there has been an increase in the availability of potent lipid-lowering therapies and increasing evidence supporting the benefits of LDL-C reduction [16]. With increasing knowledge, education, and treatment options the previously described gap in LDL-C goal achievement in high-risk individuals may have improved. In 2005, 62% of U.S. CHD patients in a very select physician group achieved an LDL-C <100 mg/dL [17]. A recent report analyzed the prevalence of high LDL-C levels across different risk levels in the National Health and Nutrition Examination Surveys (NHANES) 1999–2006 and found the prevalence of high LDL-C in the U.S. population across each risk category to be improving over the study period [18]. The longitudinal trends in U.S. LDL-C goal achievement at both the ATP III LDL-C goal of <100 mg/dL and the 2004 optional LDL-C goal of <70 mg/dL among the high risk subgroups over the past decade have not been described. Defining LDL-C goal achievement among the high-risk population and respective subgroups offers an opportunity to examine treatment gaps and identify patient populations to target with preventative therapies. The purpose of our analysis was to describe the longitudinal changes in the prevalence of LDL-C goal achievement in high-risk individuals from 1999–2008 in the U.S. population.
Methods
The National Center for Health Statistics performs the National Health and Nutrition Examination Survey (NHANES) in two-year increments to define the health and nutritional status of the United States population. The NHANES utilizes complex, stratified, multistage sampling techniques based on demographic and geographical data, assigning subjects a weight such that the sum represents a statistical model of the entire civilian non-institutionalized United States population. Methods involve identification of primary sampling units, within which, clusters of households are identified with each person in the household screened for demographic characteristics. The NHANES database has been used to develop national health standards, [19] assess disease prevalence, [20]–[23] identify risk factors for disease development and management, [24]–[25] and assess the health of the nation [26]–[27]. Detailed information on NHANES data collection is published and available at http://www.cdc.gov/nchs/nhanes.htm.
Inclusions/Exclusions
We analyzed five NHANES surveys: 1999–2000, 2001–2002, 2003–2004, 2005–2006, and 2007–2008. Included participants were ages 20–79 years and met the ATP III definition of “high risk” (see below). We excluded participants who were pregnant, received chemotherapy within 4 weeks of the exam, lacked complete lipid data including (missing total cholesterol, high density lipoprotein levels, LDL-C, or triglycerides) or blood pressure data or had triglyceride measurements ≥400 mg/dL. (Table 1).
High Risk Criteria
We defined “high risk” according to U.S. ATP III guidelines [28] that included those participants with known CHD or one or more CHD risk equivalent conditions including diabetes mellitus, cerebrovascular disease, or the presence of two or more ATP III risk factors and a Framingham risk score ≥ 20% [28]. CHD was defined in the NHANES dataset by self-reported history of myocardial infarction, CHD or angina pectoris. Diabetes mellitus was defined in the NHANES dataset by self-reported history of diabetes or of taking insulin and/or oral hypoglycemic medications. Cerebrovascular disease was defined in the NHANES dataset by self-reported history of a stroke. The number of ATP III risk factors were summed: age (men ≥45 years or women ≥55 years), hypertension (blood pressure ≥140/90 mmHg or use of antihypertensive medication), tobacco use (smoked 100+ lifetime cigarettes and currently smoking), family history of early CHD (defined in NHANES as subjects reporting a heart attack or angina in grandparents, parents or siblings <50 years of age) and high-density lipoprotein cholesterol (HDL-C) <40 mg/dL. An HDL-C ≥60 mg/dL led to subtraction of one risk factor. Framingham risk scores were calculated using formulas provided by the Framingham study (Available at: http://www.framinghamheartstudy.org/risk/hrdcoronary.html).
Lipid Goal Achievement
Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald equation, regardless of fasting status [14], [29]–[30]. Weighted mean LDL-C concentrations were calculated for those at high-risk and for the subsets with and without CHD. We evaluated achievement of both the ATP III LDL-C goal of <100 mg/dL and the 2004 optional LDL-C goal of <70 mg/dL. To determine those participants who remained eligible for pharmacotherapy initiation or intensification we evaluated the high-risk subset with an LDL-C ≥130 mg/dL. We divided this group into those with and without CHD, and further divided both groups based on medication use.
Statistical Analysis
The NHANES data sets from 1999–2008 were downloaded and imported into Microsoft Excel (version 11.2 for Macintosh, Microsoft Corp, Redmond, WA) and into SAS version 9.2 (SAS Institute, Cary, NC). Appendix S1 describes the list of NHANES item codes and descriptions. To account for the complex survey design of NHANES, SAS PROC SURVEYMEANS was used to calculate standard errors using the Taylor Linearization method [31]. The 95% confidence intervals for estimated population parameters, p-values for differences in parameters between adjacent surveys and p-values for tests of trend over time were calculated using the Wald method. A two-tailed p-value of less than 0.05 was considered to be significant.
Results
Prevalence of High-Risk Conditions
The prevalence of high-risk participants in the entire eligible population increased from 13.0% in 1999–2000 to 15.5% in 2007–2008 (p for trend 0.046) (Table 2). The prevalence of the high-risk subgroup with CHD did not significantly change over the time period of the five surveys (range 4.9% to 6.4% p = 0.33). The subgroup of high-risk participants without CHD increased from 7.5% in 1999–2000 to 10.6% in 2007–2008 (p for trend = 0.002). The prevalence trends of the diabetes mellitus subgroup increased from 5.6% to 8.6% (p for trend = <0.0001) and the cerebrovascular disease subgroup increased from 1.8% to 2.7% (p for trend = 0.032) over the five surveys. The subgroup of high risk with two or more risk factors and a Framingham risk score ≥20% (range 2.2% to 3.3% p = 0.85) did not change significantly.
LDL-C Levels in High-Risk Individuals
The mean LDL-C levels of the entire high-risk population and its subgroups with and without CHD significantly decreased over the time period of the five surveys (Table 3). The mean LDL-C in the 1999–2000 survey was 128.1 mg/dL (3.3 mmol/L) (95% CI, 122.8–133.4 mg/dL); this decreased to 106.5 mg/dL (2.8 mmol/L) (95% CI, 102.9–110.1 mg/dL) in 2007–2008 (p<0.0001). In the high-risk subgroup with CHD, the mean LDL-C in 1999–2000 was 123.2 mg/dL (3.2 mmol/L) (95% CI, 117.3–129.1 mg/dL), this level decreased to 98.3 mg/dL (2.5 mmol/L) (95% CI, 92.8–103.7 mg/dL) in 2007–2008 (p<0.0001). In the subgroup of high-risk participants without CHD, the mean LDL-C decreased from 131.7 mg/dL (3.4 mmol/L) (95% CI, 125.4–138 mg/dL) in 1999–2000 to 110.3 mg/dL (2.9 mmol/L) (95% CI, 105.3 –115.3 mg/dL), in the 2007–2008 survey (p<0.0001).
Achievement of LDL-C <100 mg/dL in High-Risk Participants
Achievement of LDL-C <100 mg/dL (<2.6 mmol/L) in high-risk participants increased from 24% in 1999–2000 to 50.4% in 2007–2008 (p for trend <0.0001, Table 3). Achievement of LDL-C <100 mg/dL for the subgroup with CHD increased from 27.0% to 64.8% (p for trend <0.0001); high-risk participants without CHD also increased, from 21.8% to 43.7% (p for trend <0.001) [Table 3]. In the 2007–2008 survey, achievement of LDL-C <100 mg/dL in the CHD subset (64.8%) was significantly greater than in the subset without CHD (43.7%, p<0.0001).
Achievement of LDL-C <70 mg/dL in High-Risk Participants
From the 1999–2000 to the 2007–2008 survey, the proportion of high-risk participants achieving an LDL-C <70 mg/dL (<1.8 mmol/L) increased from 2.4% to 17.0% (p<0.0001). The subgroup of high-risk participants with CHD that achieved an LDL-C <70 mg/dL increased from 3.4% to 21.4% (p<0.0001); high-risk participants without CHD that achieved an LDL-C <70 mg/dL also increased from 1.7% to 14.9% (p<0.0001). In the 2007–2008 survey, achievement of LDL-C <70 mg/dL did not differ significantly between the subgroups with CHD (21.4%) and without CHD (14.9%, p = 0.066).
High-Risk Participants with LDL-C ≥130 mg/dL and Not on Lipid Medications
The proportion of high-risk participants with LDL-C ≥130 mg/dL (≥3.4 mmol/L) decreased from 44.4% to 23.8% (p<0.0001) from 1999–2000 to 2007–2008. In the subset of participants with CHD, the proportion decreased from 37.2% to 18% (p<0.0001); in the high-risk subset without CHD the proportion decreased from 49.7% to 26.5% (p<0.0001). Overall, there was a significant reduction in the number of untreated high risk with LDL-C >130 mg/dL. In 1999–2000, 35.1% of the high-risk population with an LDL-C ≥130 mg/dL was not on lipid medication. This proportion decreased to 18% in the 2007–2008 survey (p = 0.0002). In 1999–2000, 25% of participants with CHD were not on lipid medications and had an LDL-C ≥130 mg/dL. This increased to 11.9% in 2007–2008 (p = 0.0013). In the subgroup of high-risk participants without CHD, 42.6% were not on lipid medication and had an LDL-C ≥130 mg/dL in 1999–2000. This proportion increased to 20.8% in 2007–2008 (p<0.0001).
Discussion
Primary Findings
This study describes U.S. improvements in LDL-C goal achievement in high cardiovascular risk populations over the last decade. Improvements were observed in participants at high risk, both with and without CHD; and at three LDL-C thresholds: <100 mg/dL, <70 mg/dL, and ≥130 mg/dL not on lipid medications.
Historical Context of LDL-C Goal Achievement in CHD
Studies from the 1980s in the U.S. demonstrated improvements in LDL-C goal achievement in the subset of the high-risk population with CHD. Analyses of the NHANES III survey described LDL-C goal achievement rates between 16.6%–18.0% in individuals with CHD [32]–[34]. A survey of primary clinicians performed in 1993 found that only 14% of the high-risk population achieved the recommended LDL-C goal of less than 100 mg/dL [35]. A comparison of the 1999–2000 and 2001–2002 NHANES survey demonstrated improved achievement of LDL-C <100 mg/dL from 27% to 41% [14]. In 2004, the NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II, a nationwide survey that recruited from the top 26% statin-prescribing physicians evaluated 4,885 patients with dyslipidemia and reported that 57% of all high-risk patients and 62% of CHD patients achieved LDL-C levels below 100 mg/dL [17]. In 2006–2007, The multinational Lipid Treatment Assessment Project (L-TAP) 2 study evaluated 9,955 dyslipidemic patients on lipid-lowering therapy. Of the 5,930 high-risk individuals with CHD, 82% were on statin therapy and 67% reached their country’s respective goal LDL-C [36]. While these studies provided optimism that achievement of LDL-C goals was improving, they were performed in highly selective clinician or patient cohorts.
This study, in contrast, measures LDL-C goal achievement levels in an U.S. representative high-risk population, providing a comparison for historical cohort studies of LDL-C goal achievement. Improvements in achieving an LDL-C <100 mg/dL goal appeared to occur in plateaus following the release of the ATP III guideline in 2001 [28] and ATP III update guidelines in 2004 [12]. Due to the cross-sectional nature of the study it is not possible to determine causality; however, release of guidelines may be one explanation for the timing of these improvements. Our study provides optimism that LDL-C goal achievement trends in the United States are improving and are consistent with the high goal achievement rates seen in highly selective cohorts.
CHD Compared with Non-CHD High Risk
LDL-C goal achievement improved in both the “high risk with CHD” subgroup and the “high risk without CHD” subgroup over the time period of the five surveys (p<0.0001 for both). Furthermore, the subgroup of “high risk with CHD” had significantly higher rates of LDL-C <100 mg/dL (p<0.0001) and lower rates of LDL-C ≥130 mg/dL (p = 0.02) compared with the “high risk without CHD” subgroup in the 2007–2008 survey. The “high risk without CHD” subset had a higher rate of LDL-C ≥130 mg/dL and not on lipid medications (20.8%) compared with the “high risk with CHD” subset (11.9%, p = 0.0099). The observed differences in LDL-C goal achievement and lipid medication use between the CHD and non-CHD subsets are likely the result of multiple causes. The high risk without CHD population in this analysis included those with diabetes mellitus, the presence of two or more ATP III risk factors and a Framingham risk score ≥ 20% or cerebrovascular disease. The lipid goal achievement gap in diabetic patients has been well described in the literature and represents numerous factors from failure to treat to the difficulty of clinical inertia in clinical practice. [37]–[39] The LDL-C achievement gap in individuals at high risk by Framingham risk score alone may be due to under recognition. Cardiovascular risk score calculation is low within primary care practices, with one report indicating cardiovascular risk calculation rates of ∼17% in primary care offices [40]. Thus, the failure to treat this group with two or more risk factors and a Framingham risk score may be the result of not appropriately identifying patients at risk. The lack of LDL-C goal achievement in those patients high risk secondary to cerebrovascular disease may also represent a combination lack of knowledge of lipid goals and clinical inertia. The importance of use of lipid lowering medication in patients with CHD is well established with a ∼30% reduction in CHD mortality. The benefits of lipid lowering medications in patients with a history of ischemic stroke is less well established with relative risk reductions ranging from 14–21% [41]–[42]. Whatever the underlying reasons may be for the LDL-C achievement gap between the high risk populations with and without CHD this finding underscores the need to target educational and awareness efforts at high-risk patients without established CHD.
Limitations/Strengths
This is a serial cross-sectional analysis with limitations inherent to the NHANES survey, including statistical modeling and selection bias. The generalizability of these findings outside the U.S. population may be limited as the NHANES are a population based statistical model of the entire civilian noninstitutionalized United States population. The NHANES questionnaires rely on self-report and may be subject to misunderstanding and recall bias. NHANES does not include incarcerated or institutionalized individuals. Some of the NHANES variables do not match the definitions set forth in the ATP III guidelines precisely so some misclassification may have occurred. For example, the NHANES defines a positive family history of CHD as a parent or grandparent experiencing a myocardial infarction or angina under the age of 50 years without gender differentiation. The ATP III guideline defines a positive family history of CHD as a risk factor if CHD afflicts a first degree male relative under the age of 55 years, or a first degree female relative under the age of 65 years [28]. The NHANES survey does not include testing for aortic aneurysms, a history of aortic surgery and does not include a question regarding claudication. Also, the NHANES survey stopped collecting data on ankle-brachial index after the 2003–2004 survey. This could result in an underestimation of those with peripheral vascular disease. However, those eligible for inclusion with ankle-brachial indices <0.9 represent a very small portion of the high risk population. Responses to questions regarding current use of lipid medications are subject to recall bias and misunderstanding. Furthermore, the cross-sectional design of NHANES makes the treatment effects of the lipid medications impossible to assess.
Conclusion
Overall, the United States population at high risk for cardiovascular disease experienced significant increases in the proportion of individuals achieving LDL-C goals of <100 mg/dL and <70 mg/dL. There also has been a significant decline in the proportion of the high-risk population with LDL-C ≥130 mg/dL and not on lipid medications.
Supporting Information
Appendix S1.
NHANES Item ID and Descriptions.
https://doi.org/10.1371/journal.pone.0059309.s001
(DOC)
Author Contributions
Conceived and designed the experiments: MT JK KK MC JS RG. Performed the experiments: MT JK KK MC JS RG. Analyzed the data: MT RG JK. Contributed reagents/materials/analysis tools: MT JK KK MC JS RG. Wrote the paper: MT JK KK MC JS RG.
References
- 1. NCEP Expert Panel (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486–2497.
- 2. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245.
- 3. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389.
- 4. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, et al. (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 1585–1591.
- 5. O’Leary DH, Polak JF (2002) Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 90: 18L–21L.
- 6. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.
- 7. Heart Protection Study Collaborative Group (2003) Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005–2016.
- 8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504.
- 9. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial–lipid-lowering arm (ASCOT-LLA). Diabetes Care 28: 1151–1157.
- 10. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, et al. (2004) Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93: 154–158.
- 11. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, et al. (1998) Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 98: 2513–2519.
- 12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732.
- 13. NCEP Expert Panel (1993) Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269: 3015–3023.
- 14. Cullen MW, Stein JH, Gangnon R, McBride PE, Keevil JG (2008) National improvements in low-density lipoprotein cholesterol management of individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart J 156: 284–291.
- 15. Ghandehari H, Kamal-Bahl S, Wong ND (2008) Prevalence and extent of dyslipidemia and recommended lipid levels in U.S. adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 156: 112–119.
- 16. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.
- 17. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, et al. (2005) Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 96: 556–563.
- 18. Kuklina EV, Yoon PW, Keenan NL (2009) Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA 302: 2104–2110.
- 19. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. (2002) 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11: 1–190.
- 20. Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303: 235–241.
- 21. Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among U.S. Adults. Diabetes Care 27: 2444–2449.
- 22. Michos ED, Blumenthal RS (2009) Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study. J Am Coll Cardiol 53: 931–935.
- 23. Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, et al. (2008) A national study of chronic disease prevalence and access to care in uninsured U.S. adults. Ann Intern Med 149: 170–176.
- 24. Sundquist J, Winkleby MA, Pudaric S (2001) Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988–1994. Third National Health and Nutrition Examination Survey. J Am Geriatr Soc 49: 109–116.
- 25. Imperatore G, Cadwell BL, Geiss L, Saadinne JB, Williams DE, et al. (2004) Thirty-year trends in cardiovascular risk factor levels among US adults with diabetes: National Health and Nutrition Examination Surveys, 1971–2000. Am J Epidemiol 160: 531–539.
- 26. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, et al. (2002) A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 136: 565–574.
- 27. Ford ES, Giles WH, Mokdad AH (2004) The distribution of 10-Year risk for coronary heart disease among US adults: findings from the National Health and Nutrition Examination Survey III. J Am Coll Cardiol 43: 1791–1796.
- 28. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370–2375.
- 29. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
- 30. Fedder DO, Koro CE, L’Italien GJ (2002) New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 105: 152–156.
- 31.
Centers for Disease Control and Prevention (2005) National Health and Nutrition Examination Survey (NHANES) analytic and reporting guidelines. Hyattsville, Maryland: National Center for Health Statistics.
- 32. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J (1998) Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 82: 61–65.
- 33. Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, et al. (2000) Impact of evidence-based “clinical judgment” on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. Arch Intern Med 160: 1361–1369.
- 34. Case CC, Jacobson TA, Roberts S, Buckley A, Murtaugh KM, et al. (2003) Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol 91: 1134–1136.
- 35. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL (1998) Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 158: 1238–1244.
- 36. Waters DD, Brotons C, Chiang CW, Ferrieres J, Foody J, et al. (2009) Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120: 28–34.
- 37. Kennedy AG, MacLean CD, Littenberg B, Ades PA, Pinckney RG (2005) The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care 28: 1029–1034.
- 38. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, et al. (2004) Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 27: 694–698.
- 39. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, et al. (2001) Clinical inertia. Ann Intern Med 135: 825–834.
- 40. Eaton CB, Galliher JM, McBride PE, Bonham AJ, Kappus JA, et al. (2006) Family physician’s knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 19: 46–53.
- 41. Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909.
- 42. Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8: 453–463.